TY - JOUR
T1 - Common Histologically Benign Tumors of the Brain
AU - Strowd, Roy E.
AU - Blakeley, Jaishri O.
N1 - Funding Information:
Address correspondence to Dr Roy E. Strowd III, Department of Neurology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, rstrowd@wakehealth.edu. Relationship Disclosure: Dr Strowd serves as deputy section editor of the Resident and Fellow Section of Neurology and has received research/grant support from the American Academy of Neurology. Dr Blakeley serves as a consultant for AbbVie Inc and receives research/grant support from the Children’s Tumor Foundation, Eli Lilly and Company, GlaxoSmithKline plc, the National Cancer Institute (U54 CA196519), the National Institute of Neurological Disorders and Stroke (R13 NS08461903), and Sanofi Genzyme. Unlabeled Use of Products/Investigational Use Disclosure: Drs Strowd and Blakeley discuss the unlabeled/ investigational use of intracavitary bleomycin for craniopharyngioma; AZD2014, bevacizumab, GSK2256098, hydroxyurea, octreotide, SMO-targeting agents, and sunitinib for meningioma; bromocriptine for pituitary tumors; and bevacizumab and everolimus for vestibular schwannoma. * 2017 American Academy of Neurology.
Publisher Copyright:
© American Academy of Neurology.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Purpose of Review: As a group, benign tumors account for the majority of primary neoplasms affecting the central nervous system (CNS). This article reviews the epidemiology, clinical presentation, neuroimaging features, and management of the most common of these tumors: meningiomas, schwannomas, and pituitary adenomas. Recent Findings: Awareness of the most common nonmalignant tumors of the CNS and their management guidelines is important as many of these tumors are managed conservatively, with neurologists playing a primary role in both surveillance and symptom management. Knowledge of the varied neurologic consequences of these tumors allows optimizing interventions that improve quality of life in people living with these tumors without incurring treatment-related complications. Awareness of the clinical features that require surgery, radiation therapy, or chemotherapy is imperative. Finally, important discoveries in both germline and somatic mutations underlying some of these lesions have contributed to the launch of several novel drug trials for these tumors. Summary: As a group, nonmalignant neoplasms are the most common neoplasms affecting the CNS in adults. Because of their unique neuroanatomic location or containment within the bony skull, these histologically benign lesions can cause significant neurologic morbidity. Management with a multidisciplinary team that includes neurologists, neuro-oncologists, radiologists, neurosurgeons, radiation oncologists, otolaryngologists, pathologists, neuropsychologists, physiatrists, and others is necessary for the optimal management of these lesions.
AB - Purpose of Review: As a group, benign tumors account for the majority of primary neoplasms affecting the central nervous system (CNS). This article reviews the epidemiology, clinical presentation, neuroimaging features, and management of the most common of these tumors: meningiomas, schwannomas, and pituitary adenomas. Recent Findings: Awareness of the most common nonmalignant tumors of the CNS and their management guidelines is important as many of these tumors are managed conservatively, with neurologists playing a primary role in both surveillance and symptom management. Knowledge of the varied neurologic consequences of these tumors allows optimizing interventions that improve quality of life in people living with these tumors without incurring treatment-related complications. Awareness of the clinical features that require surgery, radiation therapy, or chemotherapy is imperative. Finally, important discoveries in both germline and somatic mutations underlying some of these lesions have contributed to the launch of several novel drug trials for these tumors. Summary: As a group, nonmalignant neoplasms are the most common neoplasms affecting the CNS in adults. Because of their unique neuroanatomic location or containment within the bony skull, these histologically benign lesions can cause significant neurologic morbidity. Management with a multidisciplinary team that includes neurologists, neuro-oncologists, radiologists, neurosurgeons, radiation oncologists, otolaryngologists, pathologists, neuropsychologists, physiatrists, and others is necessary for the optimal management of these lesions.
UR - http://www.scopus.com/inward/record.url?scp=85037170937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037170937&partnerID=8YFLogxK
U2 - 10.1212/CON.0000000000000541
DO - 10.1212/CON.0000000000000541
M3 - Review article
C2 - 29200117
AN - SCOPUS:85037170937
SN - 1080-2371
VL - 23
SP - 1680
EP - 1708
JO - CONTINUUM Lifelong Learning in Neurology
JF - CONTINUUM Lifelong Learning in Neurology
IS - 6, Neuro-oncology
ER -